We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-0.06%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.32B
AUM Growth
+$35.6M
Cap. Flow
+$88.2M
Cap. Flow %
6.66%
Top 10 Hldgs %
68.37%
Holding
46
New
2
Increased
28
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$48.2M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33.8M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$31.9M
4
CEMP
Cempra, Inc.
CEMP
+$27.7M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$23M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$119M
2
ABMD
Abiomed Inc
ABMD
+$25.8M
3
MDVN
MEDIVATION, INC.
MDVN
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$226M 17.06%
2,066,919
-259,040
-11% -$25.8M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$182M 13.75%
1,718,658
+193,004
+13% +$21.5M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.4B
$135M 10.21%
1,737,399
+397,052
+30% +$33.8M
AMAG
4
DELISTED
AMAG Pharmaceuticals
AMAG
$78.3M 5.91%
3,273,220
+367,026
+13% +$8.41M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$52.2M 3.94%
3,804,088
+342,723
+10% +$5.01M
INSM icon
6
Insmed
INSM
$28.6B
$49.8M 3.76%
5,054,713
+263,913
+6% +$3.08M
VNDA icon
7
Vanda Pharmaceuticals
VNDA
$302M
$47.3M 3.57%
4,225,608
+194,700
+5% +$1.89M
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$5.03B
$46.7M 3.53%
1,437,730
+952,630
+196% +$31.9M
CEMP
9
DELISTED
Cempra, Inc.
CEMP
$46M 3.47%
2,787,542
+1,571,709
+129% +$27.7M
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
$41.8M 3.16%
2,408,393
+217,436
+10% +$3.99M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$39.6M 2.99%
+339,400
New +$48.2M
ZLTQ
12
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$38M 2.87%
1,391,079
+817,443
+143% +$23M
EPZM
13
DELISTED
Epizyme, Inc
EPZM
$27.8M 2.1%
2,711,381
+55,902
+2% +$623K
CELG
14
DELISTED
Celgene Corp
CELG
$27.6M 2.08%
279,600
+8,800
+3% +$910K
PRTA icon
15
Prothena Corp
PRTA
$450M
$27.6M 2.08%
788,618
+93,100
+13% +$4.05M
GILD icon
16
Gilead Sciences
GILD
$165B
$26.6M 2.01%
318,400
+15,500
+5% +$1.38M
SHPG
17
DELISTED
Shire pic
SHPG
$22M 1.66%
119,300
+13,200
+12% +$2.38M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$21.9M 1.65%
4,009,375
+458,202
+13% +$3.2M
KPTI icon
19
Karyopharm Therapeutics
KPTI
$48M
$21.1M 1.59%
209,296
+2,753
+1% +$358K
ARIA
20
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$18.7M 1.42%
2,535,117
+286,800
+13% +$2.15M
STAA icon
21
STAAR Surgical
STAA
$1.21B
$17.7M 1.33%
3,207,210
+565,335
+21% +$3.65M
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$17.6M 1.33%
1,629,076
+160,300
+11% +$1.65M
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$16.5M 1.25%
273,983
-251,479
-48% -$14.3M
HTWR
24
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$15.8M 1.19%
272,986
+21,118
+8% +$691K
ENDP
25
DELISTED
Endo International plc
ENDP
$14.4M 1.09%
923,230
+94,600
+11% +$1.96M
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q2 2016 Portfolio in Review

As of Q2 2016, Palo Alto Investors held 46 positions worth $1.32B, up 2.8% from $1.29B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Palo Alto Investors deployed $88.2M of net new capital in Q2 2016, opening 2 new positions and adding to 28 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 339,400 shares worth $39.6M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Abiomed Inc, an estimated $25.8M trimmed.

  • Palo Alto Investors's largest Q2 2016 buy was Alexion Pharmaceuticals: 339,400 shares worth $39.6M.
  • Palo Alto Investors added most to BioMarin Pharmaceuticals in Q2 2016, an estimated $33.8M increase.
  • Palo Alto Investors's biggest Q2 2016 reduction was Abiomed Inc, cutting an estimated $25.8M.
  • Palo Alto Investors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $119M.
  • Palo Alto Investors's ten largest holdings make up 68% of its $1.32B portfolio in Q2 2016.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q2 2016.
  • Palo Alto Investors's portfolio value rose 2.8% quarter-over-quarter to $1.32B.

Based on Palo Alto Investors's 13F filing for Q2 2016, filed 15 Aug 2016.